Abstract-Altered myocardial structure and function, secondary to chronically elevated blood pressure, are leading causes of heart failure and death. B-type natriuretic peptide (BNP), a guanylyl cyclase A agonist, is a cardiac hormone integral to cardiovascular regulation. Studies have demonstrated a causal relationship between reduced production or impaired BNP release and the development of human hypertension. However, the consequences of BNP insufficiency on blood pressure and hypertensionassociated complications remain poorly understood. Therefore, the goal of this study was to create and characterize a novel model of BNP deficiency to investigate the effects of BNP absence on cardiac and renal structure, function, and survival. Genetic BNP deletion was generated in Dahl salt-sensitive rats. Compared with age-matched controls, BNP knockout rats demonstrated adult-onset hypertension. Increased left ventricular mass with hypertrophy and substantially augmented hypertrophy signaling pathway genes, developed in young adult knockout rats, which preceded hypertension. Prolonged hypertension led to increased cardiac stiffness, cardiac fibrosis, and thrombi formation. Significant elongation of the QT interval was detected at 9 months in knockout rats. Progressive nephropathy was also noted with proteinuria, fibrosis, and glomerular alterations in BNP knockout rats. End-organ damage contributed to a significant decline in overall survival. Systemic BNP overexpression reversed the phenotype of genetic BNP deletion. Our results demonstrate the critical role of BNP defect in the development of systemic hypertension and associated end-organ damage in adulthood. Likewise, transgenic mouse studies looking at BNP overexpression show significantly reduced BP, and protection from cardiorenal remodeling from a variety of assaults. [10] [11] [12] Similarly, vector-mediated cardiac overexpression of BNP prohormone (pro-BNP) prevents BP elevation and the development of hypertensive heart disease in spontaneously hypertensive rats and significantly improved survival in rats with overt hypertensive heart disease. 13, 14 Consistent with these animal studies, variations in the coding regions of ANP and BNP have been causally linked to increased circulating ANP or BNP levels in humans, which in turn are associated with lower BP and a reduced risk of clinical hypertension. 15 Conversely, suboptimal BNP production or release has been implicated as a contributor in the development of human hypertension.
H ypertension is associated with considerable morbidity and mortality, presenting a major public health concern. If untreated, chronic cardiac overload results in hypertensive heart disease, characterized by cardiac remodeling, fibrosis, and stiffness, ultimately leading to heart failure. 1 Chronic hypertension can also cause nephropathy, associated with renal fibrosis and glomerular pathologies. Chronic hypertension alone is a major risk factor for stroke and arterial disease. 2 Accepted as an important endocrine organ, 3 the heart is involved in the regulation of pressure and volume by secreting hormones; atrial-natriuretic peptide (ANP) and B-type natriuretic peptide (BNP). 3, 4 These peptides are produced in response to excessive cardiomyocyte stretching 5 and maintain cardiovascular integrity through binding guanylylcyclase A (GC-A; also known as natriuretic peptide receptor 1, Npr1). 6 Acting as paracrine and autocrine factors, ANP and BNP show direct antifibrotic and antihypertrophic effects. 7 Both clinical and animal studies have established the importance of ANP and BNP in cardiorenal homeostasis. In the clinic, circulating levels of BNP has become a well-recognized biomarker with diagnostic and prognostic implications in patients with heart failure, as well as in chronic kidney disease progression. 8 In addition, human recombinant BNP, nesiritide, is available for the treatment of dyspnea in patients with acute heart failure, although studies are ongoing to explore its potential clinical use in resistant hypertension. In this regard, a small clinical study has shown, in uncontrolled hypertension, normalization of blood pressure (BP) after subcutaneous nesiritide without the need for further antihypertensive medications.
Likewise, transgenic mouse studies looking at BNP overexpression show significantly reduced BP, and protection from cardiorenal remodeling from a variety of assaults. [10] [11] [12] Similarly, vector-mediated cardiac overexpression of BNP prohormone (pro-BNP) prevents BP elevation and the development of hypertensive heart disease in spontaneously hypertensive rats and significantly improved survival in rats with overt hypertensive heart disease. 13, 14 Consistent with these animal studies, variations in the coding regions of ANP and BNP have been causally linked to increased circulating ANP or BNP levels in humans, which in turn are associated with lower BP and a reduced risk of clinical hypertension. 15 Conversely, suboptimal BNP production or release has been implicated as a contributor in the development of human hypertension. 16 Analysis of population-based samples, known as the prevalence of asymptomatic ventricular dysfunction cohort (n=2082; age >45 years), has shown impaired production and release of pro-BNP(1-108) with simultaneous reduction of circulating BNP and N-terminal-proBNP and ANP in subjects with the early stages of hypertension. 17, 18 Better defining the deleterious effects of BNP insufficiency, mouse models with genetic deletions in ANP or GC-A are characterized by marked congenital left ventricular hypertrophy (LVH) and systemic hypertension. 7 Importantly, the mouse model of systemic BNP gene (Nppb) disruption exhibits focal cardiac fibrosis on pressure overload, however, it lacks evidence of elevated BP and LVH, 19 ,20 2 hallmarks of human hypertension. Along with the absence of secondary sequelae inherent to hypertension, such as the cardiorenal interplay, the knockout mouse model poorly reflects clinical outcomes, such as progressive and chronic organ remodeling and loss of function.
Clinical biomarker studies, pharmaceutical supplemental-BNP advances, and knockout model observations, cumulatively, fall short of a systematic approach in explaining the role of BNP insufficiency on the development of hypertension and hypertension-associated complications. To elucidate the functional significance of BNP on the progression of hypertension and associated sequelae, we characterized genetically BNP-null (Nppb −/− ) rat lines. We observed progressive hypertension, cardiac remodeling, decreased myocardial function, aggravated renal pathologies, and an aggressive decline in overall survival compared with age-matched controls. This study provides a model for furthering our understanding of hypertension associated with a deficiency of the BNP system and the sequelae that arise.
Methods
All animal procedures were approved by Mayo Clinic Institutional animal care and use committee.
Animals
Nppb −/− rats were generated on Dahl salt-sensitive (Dss) backgrounds as described previously. 21 Further details, including hematology and urinalysis, tissue harvesting, and RNA extraction, are included in the online-only Data Supplement.
BP Measurement
Noninvasive BP is measured by tail-cuff using the CODA high throughput noninvasive BP system (Kent Scientific), detailed previously. 6, 13 Invasive BP measurements, including surgical procedures as detailed by StellarTelemetry, are included in the online-only Data Supplement.
Histology
For light microscopy, organs were sectioned (7-12-μm thick) from Optimal Cutting Temperature compound-embedded specimens and stained with hematoxylin and eosin or Masson's trichrome staining. Cardiac fibrosis areas were imaged by a light microscope (Axioplan). Trichrome stained tissues were analyzed by KS400 Image Analysis Software (version 3.0, Zeiss).
Confocal Microscopy
Kidney architecture in wild-type and Nppb −/− rats were analyzed by immunofluorescence using antibodies against desmin (antidesmin antibody, clone DE-B-5, Millipore), epithelial cell adhesion molecule-1 (EPCAM-1) (anti-EPCAM-1 antibody ab71916, Abcam), and podocin (rabbit antipodocin antibody, Sigma), fibroblast growth factor 2 (FGF-2 antibody [G-2] sc-365106, Santa Cruz Biotechnology, Santa Cruz, CA), aquaporin 2 (AQP2 [C-17], sc-9882, Santa Cruz Biotechnology, Santa Cruz, CA), and with the nuclear probe 4′, 6-diamidino-2-phenylindole-2HCl (Invitrogen). Fluorescent images were obtained with a Laser Scanning Microscope 510 (Zeiss, Thornwood, NY) and analyzed using Zeiss Laser Scanning Microscope Image Browser.
Optimal Cutting Temperature compound-embedded kidney tissue sections were cryosectioned to 12-μm thickness, mounted on frosted slides, and air dried. Before the incubation with specific antibodies, sections were fixed in acetone at −20°C for 20 minutes, air dried, and washed in phosphate buffered saline (PBS). To prevent nonspecific binding of immunoglobulins, tissues were blocked for 1 hour (PBS/1% fetal bovine serum). Sections were incubated with primary antibodies diluted 1:300 in blocking solution overnight at 4°C. Day 2, samples were washed 3× (10 minutes each) with PBS and incubated with secondary antibodies at 1:1000 in blocking solution (Alexa Fluor 568 donkey antimouse, Alexa Fluor 594 donkey antigoat, Alexa Fluor 647 donkey antirabbit IgG) for 1 hour at room temperature. Next, tissues were washed 3× (5 minutes each) with PBS and then incubated with 4′,6-diamidino-2-phenylindole (1:3000) for 5 minutes at room temperature. Afterward, slides were washed with PBS and then mounted with Dako Fluro Mounting Media (Dako, Carpinteria, CA).
trends of elevated BP beginning at 4 months of age, with chronically elevated diastolic, mean, and systolic BP at 6 months ( Figure 1C ). To verify the BP measurements, we implanted telemetry devices into the descending aorta and measured BP in conscious rats at 3, 6, and 9 months of age ( Figure 1D ). Telemetry results confirmed significantly elevated BP in aged Nppb −/− , consistent with the tail-cuff data set ( Figure 1C To better characterize the cardiac phenotype, we further examined 2-dimensional echocardiography images with speckle tracking to assess myocardial strain at 3 and 9 months (Table 2) , revealing a significant reduction in both radial strain, as well as radial strain rates during early (at 3 and 9 months) and late diastole (at 9 months) in Nppb −/− .
Cardiac Phenotype
We then characterized the structure of cardiac tissues at 3 and 9 months. At 3 months of age, collagen deposition in cardiac sections between Nppb +/+ and Nppb −/− were similar, as assessed by Masson's trichrome staining. However, at 9 months, Nppb −/− exhibited enhanced collagen deposition throughout the myocardium, altered structure and organized LV thrombi compared with Nppb +/+ (Figure 2A ). In addition, we observed ≈1 in 4 Nppb −/− exhibiting an abnormal cardiac structure with localized fibrosis at 3 and 9 months, and organized LV thrombi at 3 months of age. These phenotypes (fibrosis and thrombi formation) were absent in age-matched rats, as shown in Figure 2A , with knockout thrombi illustrated in ( Figure 2B ). Quantitative real-time PCR (RT-PCR) identified significantly elevated expression of canonical fibrosis-associated genes at 3 months, including tissue inhibitor of metalloproteinase 1, fibronectin-1, transforming growth factor-β, collagen type 1 α 1, and vascular endothelial growth factor ( Figure 2C ). Of note, these transcripts were upregulated at 3 months, before significant LVH, as well as deposition of connective tissues in the heart of Nppb −/− (Figure 2A, right) . In addition, telemetry data collected at 3, 6, and 9 months revealed significantly elongated QT duration in Nppb −/− rats at 9 months ( Figure 2D ). Heart rate variability was similar at early, 3 months, and later, 9 months, time points between knockout and control rats ( Figure 2D ), although cardiac expression of nerve growth factor was slightly depressed in the knockout rat.
Survival Analysis and Necropsy
Nppb −/− rats showed a significant decline in survival, mainly observed as sudden death ( Figure 2F ). Necropsy was performed on as many of the animals as possible within 24 hours of death or euthanasia. Of 8 adult Nppb −/− rats, none presented with pathological changes typical of congestive heart failure. Two presented with pericardial hemorrhage. Two animals showed sudden onset of lethargy with stroke-like balance problems, although no evidence of death from cerebral hemorrhage or ischemia was observed. All aged BNP-null rats showed darkened, stiff kidneys with rough surfaces, with blood tests indicating impaired, but functioning kidneys.
Upregulation of Hypertrophic Signaling Pathways, Cardiac Contractility Genes, and Calcium Influx in the Nppb −/− Rat Hearts
To better interrogate the primary networks affected by genetic BNP deletion at a prehypertensive state (3 months of age), we performed genome-wide expression profiling of LV tissues. Initial transcriptome analysis identified strongly downregulated genes in the Nppb −/− rat, including key factors in cardiac repair/regeneration/angiogenesis (Sdf1/ Cxcl12, Nrp1, Dll4, Notch1), actin-regulating/binding factors (Ablim1, Tmod2, and Wasf2), and factors associated with activation of cAMP pathway (Gpr4, Adcy4) or coagulation (F5; Figure 3A ). Highly activated genes in BNP ablation included a cardiac stretch sensor Lrrc39 23 , factors critical in contractility (cardiac alpha actin/Actc1 and tropomyosin1), mitogen-activated protein kinase kinase kinase family protein Tnni3k, transthyretin, factors involved in glycolysis (Pfkm) or lipid droplet accumulation (Fitm1), and adenosine kinase (Adk), responsible for phosphorylating adenosine, a cardioprotective agent ( Figure 3A ). Further bioinformatic network analysis identified the strongest toxicity responses upregulated in Nppb −/− were hypertrophy signaling, cardiac necrosis/cell death, and cardiac fibrosis ( Figure 3B ; Figures S1-S3 in the online-only Data Supplement). Importantly, familial hypertrophic cardiomyopathy genes were potently upregulated in Nppb −/− hearts ( Figure 3C ). Further analysis of key cardiac genes, responsible for cardiac contractility and relaxation, demonstrated clear trends in enhanced contractility and increased Ca2+ influx on BNP ablation ( Figure 3D ; Figure S4 ).
We confirmed the microarray data by quantitative RT-PCR and observed augmented transthyretin expression, significantly elevated Actc1, myosin heavy chain 7, and tropomyosin1 expression in Nppb −/− hearts at 3 months, compared with controls ( Figure 3E ). Likely because of cardio-compensation, we observed elevated levels of ANP-and C-type natriuretic peptide transcripts (Nppa, Nppc), as well as NP receptors, Npr1, 2, and 3 in Nppb −/− . Although Nppb transcripts no longer encode intact BNP, RT-PCR amplifying the noncoding Nppb exon 1 region also showed increased levels in Nppb −/− rats. No significant difference was observed in control 18s ribosomal RNA transcript levels between Nppb −/− and Nppb +/+ animals.
Development of Hypertensive Nephropathy
Renal function and pathology was assessed. Blood and urinalysis at study termination (9 months) revealed increased urine excretion and proteinuria in Nppb −/− , although no difference was observed in creatinine clearance between controls and surviving knockout rats ( Figure 4A ). Histologically, renal sections of Nppb −/− rats at 3 and 9 months displayed progressive glomerular alterations, characterized by a marked thickening of the glomerular basement membrane and glomerular sclerosis ( Figure 4B and 4C). Desmin, podocin, and EPCAM-1 were characterized through immunofluorescence of renal sections at 3 and 9 months. Increased desmin and decreased podocin staining was observed with age in both Nppb −/− and Nppb +/+ rats ( Figure 4D ), although more prominent in Nppb −/− rats. No notable difference was observed in anti-EPCAM-1 antibody staining ( Figure 4D ). Nppb −/− renal tissues at 9 months exhibited microcysts, prominent renal casts, and interstitial fibrosis ( Figure 4E , left panel). Staining with lotus tetragonolobus agglutinin, a marker of proximal tubules, and aquaporin 2 (AQP2), a collecting duct marker, identified microcysts were predominantly lotus tetragonolobus agglutinin-positive ( Figure 4E , middle and right panel). Renal tissues in prehypertensive Nppb −/− rats exhibited upregulation of fibrosis genes, such as transforming growth factor-β and collagen type 1 α 1, as well as upregulation of natriuretic peptide pathway genes, such as Npr1 and Npr2, at 3 months of age, as assessed by quantitative RT-PCR ( Figure 4F ).
Activation of Renal Toxicity Response Pathways in the Early Phase of Hypertension
To better interrogate the primary networks affected by BNP knockout at a prehypertensive state (3 months of age), we performed genome-wide expression profiling of renal tissues. . C, Real-time polymerase chain reaction quantification of tissue inhibitor of metalloproteinase 1 (Timp1), fibronectin-1 (Fn1), transforming growth factor-β (TGFβ), vascular endothelial growth factor (VegF), and collagen type 1 α 1 (Col1α1) transcripts are shown, relative to 18s ribosomal RNA. Nppb +/+ (n=6) and Nppb −/− (n=6) at 3 months. Total RNAs (1 μg) were analyzed. D, ECG data from telemetry implants revealed a significantly elongated QT duration at 9 months and similar heart rate variability between control and Nppb −/− rats, at 3 and 9 months. PR Duration is defined as the interval from the beginning of the P wave until the beginning of the QRS complex; RR Duration is the interval from R wave to R wave. E, Nerve growth factor expression, fold change, of cardiac tissues in Nppb +/+ (n=3) and Nppb −/− (n=3 Bioinformatic network analysis identified the strongest toxicity responses upregulated in Nppb −/− were renal necrosis/cell death, renal tubule injury, renal hydronephrosis, and kidney failure ( Figure 4G ; Figure S6A ). Analysis of the most differentially suppressed genes identified BMP signaling (Fst and Mras), LPS and interleukin-1-mediated inhibition of RXR function (Acox2), and Protein Kinase A Signaling (Ppp1r1b, Ptpro) in knockout tissues. The most differentially augmented pathways were the acute phase response signaling, calcium signaling (tnnc1), coagulation system (Serpinc1), prostanoid biosynthesis (Ptgds), and interleukin-12 signaling and production in macrophage pathway (Apoe). Most, being pathways involved in inflammatory responses providing protection from assault with nonspecific defense mechanisms or pathways involved in ischemia responses 24, 25 ( Figure S6B ). We confirmed the microarray data by quantitative RT-PCR and observed significantly elevated Slc4a4, G6pc, Nphs1, and Apoe1 expression in Nppb −/− kidneys at 3 months, compared with controls ( Figure S6C ). 
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Salt-Sensitive BP Elevation in BNP Knockout Rats
Our Nppb −/− rat was derived from a Dss rat, which presents with a nearly normal cardiovascular and renal phenotype if not conditioned with increased sodium diet. To see the influence of BNP knockout on salt-induced hypertension, we fed 10-weekold Nppb +/+ Dss and Nppb −/− Dss rats a high-salt diet for 3 weeks and monitored BP. When compared with age-matched controls, Nppb −/− rats demonstrated slightly elevated BP before the high-salt diet. Three weeks of high-sodium diet induced similar degrees of BP elevation in both Nppb −/− and Nppb +/+ Dss ( Figure 5A ). Echocardiography baseline measurements were not taken; presenting a valid limitation as to the interpretation of myocardial changes diet could induce in 3 weeks. However, comparisons between age-matched knockout and control rats 3 weeks post high-salt diet showed salt-induced hypertension with significantly wider interventricular septum, a narrowing of the LV diameter, and a thicker left ventricular posterior wall in Nppb −/− rats compared with controls ( Figure 5B ). Urinary parameters analyzed showed trends of worsened proteinuria, and lower creatinine clearance, in Nppb −/− rats compared with Nppb +/+ rats after high-sodium diet ( Figure 5C ).
Discussion
This study demonstrates that BNP deletion, in a novel rat knockout model, is characterized by progressive and sustained increase in BP. Interestingly, elevation of BP was preceded by early myocardial alteration as detected by echo assessments, immunostaining studies, and gene expression analysis. Chronic hypertension was also associated with progressive structural and functional alterations of the kidneys and reduced survival.
BNP Defect Leads to Adult-Onset Systemic BP Elevation
The healthy heart responds to cardiac overload by releasing ANP and BNP into the circulation. Once disseminated, NPs induce vasodilation and stimulate renal natriuresis through binding receptor GC-A/Npr1 26, 27 . Although ANP and BNP are functioning largely in a similar fashion, BNP has unique antiremodeling properties, greater stability, and rapid gene induction in response to cardiac stress. [27] [28] [29] [30] [31] A large association study has linked single nucleotide polymorphisms in the Nppb and Nppa locus (rs5068, rs198358, or rs632793) to increase circulating NP levels, and congruently lower systolic and diastolic BP, as well as a reduction in the risk of developing hypertension. 32 Conversely, a study on the relationships between levels of BNP and the severity of hypertension in subjects with mild, moderate, and severe hypertension has revealed that there are reduced levels of processed forms of BNP, namely N-terminal pro-BNP1-76 and BNP1-32, in the early phase of hypertension. 16 Our recent population study developed on this observation, by showing a relative deficiency of the circulating BNP precursor proBNP1-108 in prehypertensive, and early stage hypertensive subjects. 18 This indicates that 33, 34 we previously reported 14 that noninvasive (tail-cuff, CODA) BP measurements are inflated, although consistent and correlated to invasive-telemetric BP measurements. Nppb −/− rats experienced elevated BP when assessed by either noninvasive tail-cuff or by telemetry (eg, telemetry systolic BP from 127 mm Hg at 3 months to 210 mm Hg at 9 months in the Nppb −/− rats versus 126 mm Hg at 3 months and 123 mm Hg at 9 months in the Nppb +/+ rats), verifying the link between BNP insufficiency and increased BP. Progressive hypertension in the Nppb −/− rats on low-salt diet is consistent with the reported phenotype of the GC-A/Npr1 knockout mice on a 129/B6 hybrid background. 35 Intriguingly, the mouse model of genetic BNP ablation on a pure 129/Sv background is characterized by multifocal fibrosis devoid of systemic hypertension. 20 One assumption is the difference in compensatory ANP responses, that is, intact and defective ANP responses in 129/Sv and Dss rats, respectively. However, Dss rats have intact ANP responses capable of counteracting BP elevation and salt-induced hypertension. 36 We also confirmed activation of ANP and C-type natriuretic peptide expression in BNP-deficient rats ( Figure 3F ) that may provide a possible explanation for the lack of cardiac hypertrophy despite the increase in BP in Nppb −/− rats. Indeed, reports suggest that cardiac-derived C-type natriuretic peptide becomes more important in preserving heart structure and function with time in mice with left ventricular hypertrophy and heart. 37 Based on our findings, we speculated that the role of BNP in controlling BP goes, at least in part, beyond sodium regulation. In fact, the similar degree of increase in BP, observed in both the Nppb −/− and the control rats fed with high-salt diet for 3 weeks, suggested that the mechanisms of BP elevation are independent of sodium homeostasis and mutually exclusive. It is possible that other prohypertensive genetic loci in Dss rats inflate BP effect on BNP ablation, as Dss rats' exhibit higher mean BP compared with Dahl salt-resistant rats fed low-salt diets. This is primarily caused by hypertensionogenic kidneys, 38, 39 as illustrated in the paradigmatic transplant study of Dahl salt-resistant rats, with kidneys from Dss rat, resulting in hypertensive rats (ie, hypertension following the kidney). 39 From testing the salt-induced hypertensive sensitivity of Nppb −/− rats, we have shown that both Nppb +/+ and Nppb −/− rats are equally sensitive to high-salt-induced hypertension. Thus, the mechanism of BP elevation induced by genetic deletion of BNP and salt-induced hypertension in Dss rats is mutually exclusive.
Early Alteration of Cardiac Function and Structure in Nppb −/− Rats
Standard echocardiography measurements demonstrated earlier LVH (ie, 3 months) in Nppb −/− rats, with impaired myocardial function as detected by strain and strain rate (Tables 1  and 2 ), along with maintained ventricular emptying. Cardiac structure deterioration was predominantly similar to that in Nppb +/+ rats at 6 and 9 months, showing an aging effect on the cardiac structure of the control rats. However, myocardial function was significantly and further impaired in the Nppb −/− rats at 9 months as indicated by speckle tracking data (ie, global circumferential strain). The decreased strain and the strain rate data coincide with the demonstrated increase in myocardial fibrosis at 9 months (Figure 2 ), which may have contributed to the observed decrease of myocardial shortening and increased stiffness. The augmented fibrosis deposition could have ultimately caused the QT elongation documented at 9 months ( Figure 2D ) in the Nppb −/− rats. The hypertensive prone phenotype of the Dss background of our model may have blunted the differences observed between the Nppb −/− and the Nppb +/+ rats, and in part explains the aging effects on cardiac function and structure observed at echocardiography examinations performed at 6 and 9 months. Nevertheless, the more profound and earlier alterations observed resulting from BNP deletion were likely responsible for the increase in sudden death. The reduced number of surviving Nppb −/− rats at 6 and at 9 months could also have contributed to the lack of statistical difference. An alternative cause between the knockout phenotype of cardiac impairment, QT elongation, and sudden death may be because of autonomic innervation.
Although not a direct measurement of autonomic innervation, levels of nerve growth factor expression within innervated tissues, such as the myocardium, roughly correspond to the innervation density. 40 Nerve growth factor in knockout rats was decreased 1.26-fold from age-matched controls, suggesting the increased cardiac impairment in the Nppb −/− rats was not because of innervated myocardial tissues. We further investigated heart rate variability, as an indirect assessment of sympathetic and parasympathetic activation. Previous studies have shown that BNP, like other NPs, increases heart rate and electric conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium. 41 However, heart rate variability was not different between groups at 3 and 9 months. Together these data suggest that the autonomic nervous system may not play a critical role in the cardiac impairment of knockout rats.
Activation of Cardiac Remodeling Pathways in the Early Phase of Hypertension
Chronic BP elevation leads to cardiac remodeling, hypertrophy, increased fibrosis, and stiffness, ultimately resulting in a decline of cardiac function. Studies have previously demonstrated that the NPs possess antihypertrophic and antifibrotic effects through binding receptor GC-A/Npr1. In addition, the antihypertrophic actions of the ANP/GC-A system are independent of BP. 42 GC-A/Npr1-null mice exhibit developmental cardiac hypertrophy, 43 with antihypertensive treatments capable of normalizing BP elevation, but ineffective in reducing heart size. 44 In contrast, we found no evidence of cardiac hypertrophy in 1-and 2-month-old Nppb −/− rats. Similarly reported in BNP knockout mice, 20 this suggests that physiological levels of BNP do not play a major role in developmental cardiac growth. In contrast, BNP-null rats demonstrated significant increases in LV mass and posterior wall thickness at 3 months, which was in concert with the beginning of elevated BP. Significant increases in cardiac stiffness and fibrosis were evident in Nppb −/− at 9 months, reinforcing the progressive nature of cardiac remodeling during hypertension. It is also notable that LV mass, along with activation of cardiac hypertrophy signaling pathway genes, preceded significant chronically elevated BP in
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. This is in agreement with our previous observation in spontaneously hypertensive rats where cardiac BNP transduction prevented the development of cardiac remodeling, partly independent of BP reduction. 13 Here, at 3 months of age, BP elevation in knockout animals was marginal. Consistent with this, is the population-based study in adolescents and young adults demonstrating 2-fold higher prevalence of LVH among prehypertensive individuals. 45 In addition, we observed marked upregulation of cardiac fibrosis-associated genes, such as collagen type 1 α 1 and transforming growth factor-β, before significant cardiac connective tissue deposition, in BNP-null rats at 3 months. Together with what we previously reported in spontaneously hypertensive rats and in humans with prehypertension, 6 ,13,14 we suggest that relative BNP insufficiency leads to preactivation of cardiac hypertrophic and profibrotic programs, before the development of true hypertension, contributing to a worsening of cardiac remodeling in later stages of life.
Renal Protective Effects of BNP

Nppb
−/− rats at 9 months demonstrated higher levels of protein excretion and polyuria, with relatively unchanged creatinine clearance, as an estimate of glomerular filtration rate. This is in agreement with early studies assessing the accuracy of filtration markers, such as creatinine, in chronic kidney disease. Authors inferred that patients would require a loss of >50% in glomerular ultrafiltration in order for serum creatinine levels to increase above the normal range. 46 It is then possible that patients with chronic kidney disease preserve serum creatinine levels within the normal range, despite significantly reduced renal function. 47 Knockout renal tissues further developed parenchymal remodeling, characterized by renal fibrosis, dilated proximal tubules, renal cast formation, and increased glomerular injuries, more severely than age-matched controls. Specifically, we observed a tendency to express higher desmin and decreased podocin immunofluorescence, 2 markers of podocyte damage, in the Nppb −/− rats. This was accompanied by microcysts formation predominantly at proximal tubules level, as indicated by positive lotus tetragonolobus agglutinin staining ( Figure 4E ). These pathological changes are characteristic of hypertensive nephropathy and interestingly presented before an apparent reduction of renal function (ie, decline in creatinine clearance). Progressive renal remodeling largely coincided with BP elevation, implying that chronic BP elevation is crucial to renal pathophysiology in Nppb −/− rats. Nevertheless, the modest but significant increase in glomerular injuries, as well as the activation of fibrosis-associated genes at 3 months, before considerable hypertension, highlights the natural renoprotective effects of BNP that go beyond BP control. Like cardiac remodeling, it is conceivable that the BNP insufficiency may play a role in worsening of renal complications also in human hypertension.
Decline in the Survival of the Nppb −/− Rats
A population-based study demonstrated that, compared with normotensive subjects, hypertensive subjects acquire shorter life expectancies and have fewer cardiovascular disease-free years. 48 A hallmark of our BNP-deficient rats was a shortened life expectancy. Most rats died before 9 months, whereas no control rats died during the study period. Morbidity and mortality onset was sudden, unexpected, with several rats found dead, or extremely weak (hunched and lethargic), a day following reasonable health. Because a clearly defined cause that precipitated lethal events remained unclear, we speculate that several factors contributed to the reduced survival. Because knockout rats at 3 and 9 months frequently presented with substantially remodeled hearts, localized fibrosis, and notable thrombi, it is conceivable that cardiac arrest or embolism contributed to the sudden death. In addition, we found elongated QT intervals, possibly secondary to the marked myocardial fibrosis, at 9 months in Nppb −/− rats, that could also explain the risk of sudden death. It should be noted that a prolonged QT interval is a major predictor of mortality in hypertensive patients. 49, 50 Finally, a significantly deteriorated renal structure could also have contributed to the increased risk of death in these Nppb −/− rats.
Reversal of BNP Knockout Phenotypes by AAV9 Vector-Mediated Long-Term BNP Overexpression
An inherent problem associated with zinc-finger nuclease generated knockouts is off-target deletions. 51, 52 To confirm that the prevailing Nppb −/− phenotypes observed, namely cardiac remodeling, hypertension, polyuria, and reduced survival, were specific to the genetic ablation of BNP, and not because of an off-target deletion, we conducted a pilot study where AAV vectors were used to deliver cardiac BNP in Nppb −/− rats. Neonate littermates were randomly divided into reversal or control groups. Reversal pups received AAV9 (adeno-associated virus serotype 9) vectors constitutively expressing endogenous rat BNP and were followed with littermate controls for 9 months. Vector genomes were quantified at 3 and 9 months as 2.7E7 and 2.13E5 vector genomes per μg of total cardiac DNA, respectively. When the codonoptimized rat BNP transgene expression levels were analyzed by RT-PCR, expression levels at 3 months were significantly elevated (17.6-fold) in treated animals, whereas no significant elevation in transgene expression was noted at 9 months, suggesting a gradual reduction in vector genomes in treated rat hearts. Vectormediated BNP overexpression in Nppb −/− protected against the cardiac hypertrophy and remodeling observed in untreated littermates ( Figure S7A ), significantly suppressed BP at 3 and 6 months compared with Nppb −/− ( Figure S7B) , and although vector genomes, as well as vector-mediated expression, had waned significantly over time, treated animals were protected against the polyuria experienced by Nppb −/− littermate controls at 9 months ( Figure S7C ). Six of 7 BNP-treated Nppb −/− rats survived the study duration of 9 months, with 1 rat dying because of anesthesia malfunction, verifying that BNP insufficiency was responsible for the key phenotypes; increased BP, cardiac remodeling, polyuria, and reduced survival found in Nppb −/− rats.
Novel Small Animal Model for Human Hypertension
Rodents provide excellent small animal models to study cardiorenal diseases. In particular, rats are favored for cardiovascular diseases over mice because of their inherently similar cardiovascular physiology to humans. Their larger size facilitates higher resolution imaging, increased blood, and tissue harvest potential, as well as surgical possibilities. Currently, various genetic and spontaneous rodent models are available to study hypertension. However, none faithfully recapitulate the development of human hypertension with BNP insufficiency. Rodent models with genetic Nppa or GC-A knockout exhibit congenital hypertrophy with systemic BP elevation. Nppb −/− mice show focal cardiac fibrosis, however, they do not present with progressive or naturally occurring BP elevation. In addition, BNP knockout mice do not develop secondary pathologies characteristic of human hypertension, such as polyuria, renal parenchymal remodeling or glomeruli pathologies, and altered myocardium. The Nppb −/− rat exhibited adult-onset, progressive, systemic hypertension, with hypertension-associated cardiac and renal complications. In addition, Nppb −/− rats demonstrate LVH and sudden cardiovascular death without notable cardiac dysfunction, providing a unique platform to model metabolic and physiological properties of human hypertension. At 6 months, although the main cardiac functional parameters in the Nppb −/− rats were not different from their age-matched controls, LV mass remained slightly higher. The lack of progressive worsening of LVH certainly represents a major difference in the evolution of hypertension between humans and our model. This difference is likely related to the background strain (ie, hypertensive prone phenotype) of our Nppb −/− rats (ie, Dss) that it is characterized by a rapid transition from hypertrophied to dilated cardiomyopathy. 53 Despite this inconsistency, this new model still allows for the assessment of interventions for hypertension, myocardial dysfunction (Table 2) , and associated end-organ complications in a setting most closely mimicking human hypertension.
Perspectives
Our study furthers the role of BNP deficiency in developing hypertension and provides a unique and novel animal model of chronic hypertension with associated organ damage and reduced survival. Our study also warrants further interrogation on the applicability of chronic BNP-based therapies for treating progressive hypertension and associated end-organ damages. 
BNP DELETION LEADS TO PROGRESSIVE
SUPPLEMENTAL INFORMATION METHODS
Animals.
Nppb -/-rats were generated on Dahl Salt Sensitive (Dss) backgrounds as described previously 1 . Briefly, strains were generated by microinjection of CompoZr ZFNs (Sigma) into one-cell SS/JrHsdMcwi (S) rat embryos and then implanted into pseudopregnant Sprague Dawley females 2 . A total of 22 Nppb -/-and 12 of Nppb +/+ male rats were used for this study. A separate group of Nppb -/-(n=4) and Nppb +/+ (n=4) male rats underwent three weeks of high salt diet beginning at 10 weeks of age. For reversal studies, neonates were generated from breed pairs, and littermates were randomly assigned to two groups: (group 1) received an intraparenteral injection with proBNPexpressing adeno-associated virus serotype 9 (AAV9) vector (1 x 10 11 genome copies/rat), while littermates were injected with either PBS, or a luciferase expressing AAV9 vector (group 2). The effects of sustained proBNP expression were analyzed three, six, and nine months post injection.
Tissue harvesting, RNA extraction. For tissue studies (qPCR, Histology, Immunohistochemistry), rats were anesthetized with isoflurane, jugular vein bled, and then euthanized with carbon dioxide. Organs were removed, and either frozen in 2mg pieces in 1.5mL SC Micro Tube, Sarstedt (Numbrecht, Germany) and stored at -80°C for later mRNA extraction, or frozen in Tissue-Tec O.T.C Compound (Miles, Elkhart, IN) freezing media, and stored at -80°C until use. For histology, organs were brought to -20°C overnight, and cross-sectioned in a cryostat at -20°C, in 7-12 µm thick sections, then subjected to either Masson's trichrome staining, or hematoxylin and eosin staining (American Master Tech, Lodi, CA) as per manufacturer's instructions. For RNA extraction, 1mg of frozen tissue was homogenized in TRIzol (500ul; GIBCO BRL, Gaithersburg, MD) and then subsequent phenol-chloroform extraction according to manufacturer's instructions. 2 µg of total RNA was then reverse transcribed into cDNA by RNA to cDNA EchoDry Premix (Clontech Laboratories, Mountain View, CA) and the resulting cDNA was mixed with gene-specific primers and assayed by quantitative-pcr (qPCR). 1 μl of cDNA were added to 2.5 µl of a 10x Primer assay (Supplemental Table 1 ) and 12.5 µl of 2x Master Mix FastSYBR® Green (Applied Biosystems, CITY and STATES), and 9 µl of sterile water was added to reach a final volume of 25 µl. The amplification reactions were performed in a 7300 Real Time PCR System (Applied Biosystems) following the conditions of standard protocol for FastSYBR Green® (same for all genes): After denaturation of the cDNA and enzyme activation at 95°C for 5 minutes, 40 cycles were performed in 2 steps (95°C for 10 seconds and 60°C for 30 seconds). The expression of the ribosomal RNA (18s RNR) was employed as a housekeeping gene, and expression levels are presented as relative transcripts to 18s RNR expression.
Hematology and urinalysis.
Plasma BNP concentrations were determined using commercially available EIA (Assay pro, St. Charles, MO). Rats were placed in metabolic cages that provided free access to tap water and food pellets. Overnight urine volume and urinary sodium, potassium, albumin, creatinine and protein excretion were measured. For toxicological and pharmacological tests, hematological parameters (VetScan HM2 Hematology System; 100 µl blood in EDTA for WBC counts, WBC histogram, Hb, Hct, MCV, MCH, MCHC, RDW, graphic RBC histogram, PLT count, MPV, PCT, PDW and Graphic platelet histogram) and chemistry (VetScan Classic; 100ul blood in lithium heparin; ALB, ALP, ALT, AMY, BUN, CA++, CRE, GLOB, GLU, K+, Na+, PHOS, TBIL, TP) were measured ( Figure S5 ).
Non-invasive BP measurement.
Blood pressure is measured by tail-cuff using the CODA high throughput non-invasive BP system (Kent Scientific), detailed previously 3, 4 . Briefly, the animal is placed in the holder at least 10 minutes prior to obtaining pressure measurements. Acclimatization is accomplished through training sessions. A minimum of 10 readings were taken, and the mean of acceptable readings (as determined by the software instrument) were recorded per animal, at each observation time.
Telemetry Surgical Procedure:
Surgical procedures were carried out as detailed by StellarTelemetry. Briefly, rats were anesthetized first in an induction chamber, and then maintained at 1.5-2% Isoflurane via a nose cone. Rats are then shaved, and incised through the midline linea alba. The intestines cephalad and lateral were displaced exposing the posterior abdominal wall and the aorta. Blunt dissection revealed the aorta, and a 28 gauge needle was used to accomplish the arteriotomy. The pressure sensor was implanted and secured using 4-0 silk suture and the arteriotomy was closed by tissue adhesive. The muscle layer of the abdomen was then closed with the implant inside using 4-0 prolene suture, and electrocardiographic leads were then sutured to muscle using 4-0 silk. Skin incisions were closed using skin staples, and removed 7-10 days post-surgery. Although a total of 12 rats were instrumented with telemetry in each group, due to a manufacture defect, we were able to assess recorded parameters in 2 Nppb -/-and in 2 Nppb +/+ rats at 3 months, in 3 Nppb -/-and in 5 Nppb +/+ rats at 6 months, and 3 Nppb -/-and 3 Nppb +/+ rats at 9 months . Echocardiography (ECHO) for non-invasive assessment of cardiac function and structure. Standard ECHO examinations were performed at 3, 6 and 9 months in Nppb-/-and control rats. All ECHO examinations, ECHO analysis, and speckle tracking were performed by a skilled sonographer (S.H) blinded to treatment, as previously described 4, 5 . Briefly; a Vivid 7 ultrasound machine (General Electric, Waukesha, WI) with a GE Vivid 7 10S transducer were used to collect ECHO data. Images were taken, at a depth of 2-2.5cm, of the parasternal short-axis left ventricular view, using the papillary muscles as anatomical landmarks. Images were then exported to a separate workstation for analysis using EchoPAC with Q-analysis software (General Electric, Waukesha WI). Radial and circumferential strain and strain rates were analyzed as previously published 6, 7 . Briefly, the left ventricle (LV) was divided into 6 segments, the endocardial border was traced, and the outer border was adjusted to fit the epicardial contour. Q-analysis software then automatically selected speckles within the myocardium, tracked, and computed strain and strain rate in radial and circumferential directions over the segments of the left ventricle through a cardiac cycle. The average of individual segment strain and strain rates were calculated for peak systolic, early-, and late-diastole. LV studies were measured using anatomic M-mode of the 2D B-mode images. CRYAB,CA4,BCL6,PKN2,MYC,YWHAQ,ATP1A1,PAK1,FGFR4,PPP3R1,SLC22A1,CAV1,PLCB1,PPM1A,HIPK2,CALB1,WT1,CU  L4B,TJP2,ATF3,SLC2A1,RAC1,FGD1,IER3,PTGDS,PFKM,DUSP1,TMX1,IGFBP3,NEIL1,TFRC,VDAC1,AGTR1,CDK2,LDHA,APO  E,TCF4,PIK3CA,GSTM5,TFAP2B,Nrg1,GAPDH,DDN,JAK2,NPHS1,AQP3,NFAT5,AR,KL,IGF1R,NAMPT,CTNNB1,CASP8,NFE2L  2,ATP13A2,ATN1,PRNP,DNASE1,ITGB1,PAK2,BGN,MAP3K1,AQP11,HIP1,F3,SULT2B1,GRB10,STRA6,COX11,SLC7A9, 
